TY - JOUR T1 - Renewed safety warnings for yellow fever vaccine JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 148 LP - 148 DO - 10.1136/dtb.2019.000057 VL - 57 IS - 10 A2 - , Y1 - 2019/10/01 UR - http://dtb.bmj.com/content/57/10/148.abstract N2 - Review of: Medicines and Healthcare products Regulatory Agency. Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older. Drug Safety Update 2019;12:1.Key learning pointsTwo cases of fatal adverse reactions following immunisation with yellow fever vaccine have prompted the Medicines and Healthcare products Regulatory Agency to issue a safety update.Yellow fever vaccine must not be administered to anyone with a medical history of thymus dysfunction or who is immunosuppressed.Extreme caution must be used, and a careful risk assessment conducted, before administering yellow fever vaccine to people aged 60 years and older.Healthcare professionals are reminded that yellow fever vaccine must not be given to people who may be immunosuppressed, those with a history of … ER -